Vynfinit progress sees near doubling of Endocyte value
This article was originally published in Scrip
Investors responded enthusiastically to two positive pieces of news from Endocyte on Friday 21 March. First, experts on the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM) recommended granting conditional marketing authorisation for Vynfinit (vintafolide) to treat women with a sub-type of platinum-resistant ovarian cancer for which there are limited approved treatment options. Second, the company reported that in the Phase IIb TARGET trial, Vynfinit plus docetaxel, as a potential second-line treatment of non-small cell lung cancer (NSCLC), met the primary endpoint of improving progression free survival versus docetaxel alone.